Selection criteria for bacterial strains and bacteriophages for the formation of industrial collection of specifically lysing bacteria: Klebsiella, Echerichia, Proteus, Pseudomonas, Staphylococcus
Abstract
The present article submits the results of work on the isolation and study of biological properties of bacteriophages, active against Klebsiella, Echerichia, Proteus, Pseudomonas, Staphylococcus. It also shows the results of the study such as: lytic activity, the definition of the spectrum of lytic action, sensitivity to damaging environmental factors: pH, temperature, freeze drying. The data of molecular genetic studies are provided.
About the Authors
E. N. Siatchikhina
«FORT» LLC (Biopharmaceutical company FORT)
Russian Federation
Microbiologist of Department of medical immunobiological medicines development
Russian Federation
Microbiologist of Department of medical immunobiological medicines development
P. A. Nabatnikov
«FORT» LLC (Biopharmaceutical company FORT)
Russian Federation
Head of Department of medical immunobiological medicines development
Russian Federation
Head of Department of medical immunobiological medicines development
S. A. Korovkin
«FORT» LLC (Biopharmaceutical company FORT)
Russian Federation
Deputy Director General. Doctor of Medical Sciences, professor
Russian Federation
Deputy Director General. Doctor of Medical Sciences, professor
A. V. Katlinsky
«FORT» LLC (Biopharmaceutical company FORT)
Russian Federation
Director General. Doctor of Biological Sciences
Russian Federation
Director General. Doctor of Biological Sciences
G. M. Ignatyev
«FORT» LLC (Biopharmaceutical company FORT)
Russian Federation
Deputy General Director for science. Doctor of Medical Sciences, professor
Russian Federation
Deputy General Director for science. Doctor of Medical Sciences, professor
References
1. Drulis-Kawa Z, Majkowska-Skrobek G, Maciejewska B. Bacteriophages and phage-derived proteins-application approaches. Curr Med Chem. 2015; 22(14): 1757–73.
2. Kosinets AN, Frolova AV, Bulavkin VP, Okulich VK. Antibiotic resistance. New features of the antibacterial effects. Vestnik VGMU 2014; (2): 70–7 (in Russian).
3. Pires DP, Vilas Boas D, Sillankorva S, Azeredo J. Phage Therapy: a Step Forward in the Treatment of Pseudomonas aeruginosa Infections. J Virol. 2015; 89(15): 7449–56.
4. Adams M. Bacteriophages. Moscow: Inostrannaya literatura; 1961 (in Russian).
5. Levin B, Bull JJ. Phage Therapy Revisited: The Population Biology of a Bacterial Infection and its Treatment with Bacteriophage and Antibiotics. The American Naturalist 1996; 147: 881–98.
6. Barrow PA, Soothill JS. Bacteriophage Therapy and Prophylaxis: rediscovery and renewed assessment of the potential. Trends Microbiol 1997; 5: 268–71.
7. Aleshkin AV, Volozhantsev NV, Svetoch EA, et al. Bacteriophages and means probiotics and decontamination of food products. Astrahanskiy meditsinskiy zhurnal 2012; 7(3): 31–9 (in Russian
8. Khairullin IN. The role of the microflora in the surgical department in the development of postoperative complications of surgical wounds and their correction by means of bacteriophages. Cand. Med. Sci [thesis]. Kazan; 2004 (in Russian).
9. Kruglova LS. Polyvalent bacteriophages: prospects for application in dermatology. Klinicheskaya dermatologiya i venerologiya 2015; (1): 72–6 (in Russian).
10. Sulakvelidze A, Alavidze Z, Glenn Morris J. Bacteriophage Therapy. Antimicrob Agents Chemother. 2001; 45(3): 649–59.
11. Kutter E. Phage therapy: bacteriophages as antibiotics. St. Petersburg; 2001 (in Russian).
12. Levin BR, Bull JJ. Population and evolutionary dynamics of phage therapy. Nat Rev Microbiol. 2004; 2(2): 166–73.
13. Skurnika M, Strauch E. Phage therapy: facts and fiction. Int J Med Microbiol. 2006; 296(1): 5–14.
14. Zurabov AYu, Karkischenko NN, Popov DV, Zhilenkov EL, Popov VM. Creating a national collection of bacteriophages and principles for the development of therapeutic and prophylactic phage preparations. Biomeditsina 2012; (1): 134–8 (in Russian).
15. Skurnik M, Pajunen M, Kiljunen S. Biotechnological challenges of phage therapy. Biotechnol Lett. 2007; 29: 995–1003.
16. Tanji Y, Shimada T, Yoichi M, Miyanaga K, Hori K, Unno H. Toward rational control of Escherichia coli O157:H7 by a phage cocktail. Appl Microbiol Biotechnol. 2004; 64: 270–4.
17. Chibani-Chennoufi S, Sidoti J, Bruttin A, Kutter E, Sarker S, Harald Brüssow H. In Vitro and In Vivo Bacteriolytic Activities of Escherichia coli Phages: Implications for Phage Therapy. Antimicrobial agents and chemotherapy 2004; 48: 2558–69.
18. Darbeeva OS, Mayskaya LM, Obuhov YuI. Preclinical studies of bacteriophages. In: Mironov AN, ed. Guidelines for preclinical studies of drugs (immunobiological drugs). Part II. Moscow: Grif i K; 2012. P. 237–40 (in Russian).
19. Thiel K. Old dogma, new tricks — 21st Century phage therapy. Nat Biotechnol. 2004; 22(1): 31–6.
20. Lu TK, Koeris MS. The next generation of bacteriophage therapy. Curr Opin Microbiol. 2011; 14(5): 524–31.
21. Barrow PA, Soothill JS. Bacteriophage therapy and prophylaxis: rediscovery and renewed assessment of potential. Trends Microbiol. 1997; 5(7): 268–71.
22. Tikunova NV, Vlasov VV. Bacteriophages — the enemies of our enemies. Nauka iz pervyh ruk 2013; 2(50): 58–69 (in Russian).
23. Bondarenko V. New horizons of bacteriophagy. Bulleten Orenburgskogo nauchnogo tsentra UrO RAN 2013; (4): 1 (in Russian).
Review
For citations:
Siatchikhina E.N., Nabatnikov P.A., Korovkin S.A., Katlinsky A.V., Ignatyev G.M. Selection criteria for bacterial strains and bacteriophages for the formation of industrial collection of specifically lysing bacteria: Klebsiella, Echerichia, Proteus, Pseudomonas, Staphylococcus. BIOpreparations. Prevention, Diagnosis, Treatment. 2016;16(2):90-95. (In Russ.)
Views:
551
Email this article 